# The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.

*biotech · news · 2026-04-22 · The Manila Times*

## Key points

- GHIT Fund is investing JPY 700 million in preclinical development of a novel antimalarial drug.
- A new trial in Kenya, Senegal, and India will seek WHO registration for fosravuconazole for eumycetoma.
- No mycetoma drug had been evaluated via randomized controlled trials before GHIT's Sudan trial.
- GHIT also funds three new antimalarial projects focusing on novel drug targets and mechanisms.

**Companies:** Tanabe Pharma Corporation, GlaxoSmithKline Investigacion y Desarrollo, S.L., DAIICHI SANKYO COMPANY, LIMITED, Medicines for Malaria Venture, Eisai Co., Ltd.
**Countries:** Japan, United States, Kenya, Senegal, India

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/22/tmt-newswire/pr-newswire/total-investment-of-approx-usd-85-million-in-malaria-and-ntd-rd-projects-with-partners-including-mmv-gsk-tanabe-pharma-eisai-and-dndi/2325625)

---

Canonical: https://newsio.io/n/370c0511-d926-42e0-9bec-c4510393c0c4/the-global-health-innovative-technology-ghit-fund-announced-today-a-total-invest
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works